Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1B Investigator Initiated Study To Evaluate The Preliminary Activity, Safety And Tolerability Of ETC-159 In Combination With Pembrolizumab In Advanced MSS/pMMR Ovarian Cancers.

NCT06513624 is registered in ClinicalTrials.gov with National University Hospital, Singapore as lead sponsor.

NCT NCT06513624
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06513624 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1B Investigator Initiated Study To Evaluate The Preliminary Activity, Safety And Tolerability Of ETC-159 In Combination With Pembrolizumab In Advanced MSS/pMMR Ovarian Cancers.
Lead sponsor
National University Hospital, Singapore
Phase
Phase 1
Overall status
Recruiting
Start date
December 9, 2024
Completion date
June 30, 2027
Enrollment
16 (estimated)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

with mss/pmmr advanced, platinum-resistant ovarian cancer